SEC Form 4 · accession 0001209191-16-095726
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David R Walt
Director
Period of report
Feb 2, 2016
Accepted (ET)
Feb 4, 2016 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 2, 2016 | P | 4,395 | $2.3684 | A | 116,998 | D | |
| Common StockF3 | Feb 3, 2016 | P | 4,018 | $2.2725 | A | 121,016 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These purchases were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2015.
- F2Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.26 to $2.475 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
- F3Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.23 to $2.30 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.